Indeed, WIP1 inhibitors, including GSK2830371 (GSK), are currently being pursued as anticancer drugs based on their ability to reactivate p53.27–29 We thus tested the effect of GSK on CSC properties in NSCLC cells. Here, TP53 is linked to non-small cell lung carcinoma.